AUS
NZ
UK
CA
USA
IND
_06_04_2026_05_16_02_212823.jpg)
Highlights
4DMedical receives U.S. reimbursement approval for its lung imaging software CT:VQ.
Medicare backing confirms both regulatory and commercial viability of the company’s technology.
New milestone could accelerate hospital adoption and broaden diagnostic access.
Biotechnology company 4DMedical (ASX:4DX), listed on the ASX 300, has drawn market attention after confirming that the U.S. Centers for Medicare and Medicaid Services will reimburse its flagship CT:VQ lung imaging software. The development marks a notable step forward in the commercialisation journey of a product that integrates artificial intelligence with respiratory diagnostics.
Having already secured regulatory clearance in the U.S., the addition of reimbursement transforms CT:VQ into a commercially supported product in one of the world’s most complex healthcare markets. This combination strengthens the position of 4DMedical to scale its offering across clinical networks and hospital systems.
How Does Reimbursement Impact the Broader Commercial Strategy?
The approval of reimbursement by a major U.S. health agency is more than a financial milestone; it validates the economic feasibility of using 4DMedical’s imaging solution in real-world clinical environments. With Medicare support in place, hospitals and imaging providers gain assurance around billing, making the technology easier to integrate without imposing added cost burdens.
From a system-level standpoint, 4DMedical’s approach does not require specialised nuclear imaging facilities, which opens its usage to a broader range of institutions. This accessibility complements the company’s mission to decentralise and modernise lung diagnostics using AI and data-driven insights.
What Advantages Does CT:VQ Offer Over Traditional Diagnostic Methods?
4DMedical's CT:VQ uses four-dimensional imaging technology to deliver functional insights into lung ventilation without the use of radioactive agents. This non-invasive method helps healthcare providers better detect and monitor respiratory conditions with higher granularity.
In contrast to conventional scans that may be limited in functional output, CT:VQ’s data-rich imaging enables early detection of abnormalities and more informed clinical decisions. The platform's integration of AI enhances accuracy, offering a more comprehensive picture of lung performance.
Can 4DMedical Extend Reach Within the U.S. Healthcare System?
With both reimbursement and regulatory approvals secured, 4DMedical is positioned to initiate broader commercial outreach to imaging centres, hospital networks, and health systems. Its solution aligns with market demand for scalable, tech-driven diagnostics that improve patient outcomes while optimising resource use.
The recent Medicare development could help forge strategic partnerships, particularly with providers looking for alternatives to traditional nuclear medicine diagnostics. It also opens potential access to government-backed reimbursement streams that ensure consistent adoption across different healthcare models.
What Does This Mean for the Australian Medical Tech Sector?
The recent traction gained by 4DMedical illustrates the growing global relevance of Australian-developed medtech innovations. The ability to penetrate and gain commercial standing in the U.S. healthcare market places the company among a niche group of domestic firms making an international impact.
As healthcare systems continue shifting towards technology-backed diagnostics, companies that blend regulatory compliance with scalable digital solutions stand to reshape how care is delivered. For 4DMedical, this moment underscores years of development aimed at transforming lung health diagnostics into a widely accessible and economically viable practice.
